Skip to main content

Relay Therapeutics, Inc Investor Event Transcript, Nov 18, 2026

Relay Therapeutics, Inc. (RLAY)

Relay's CEO said its PI3K alpha mutant-selective asset, Zovega, is moving into three pivotal trials, including a second-line breast cancer trial expected to be fully enrolled by mid-2027. The company reported $849 million of cash, which should last well into 2029. Relay plans an update on vascular anomalies data at ASH in December. AI summary

Investor Event Transcript 2026-11-18 For: 2026-12-31
Added on November 19, 2026

Conference Transcript - RLAY 2026-11-18

Akash, Analyst — J.P. Morgan

Thanks so much, everyone. Day three is one of those health care conferences you can't leave on the first day. You know, you got to stick around. And I appreciate everyone being here in the afternoon on day three. Energy levels are high, and they are for me because I'm always excited to talk with the Relay team and Sanjeev. Why don't we hand it off to you for some intro remarks, and we'll get going.

Sanjeev Patel, CEO

Thanks, Akash, for the invite, and thank you for enduring the first three days of this to get to this one. I appreciate you all attending. As you know, 2026 has been a very productive year for Relay. We have Zovega, which is our PI3K alpha mutant selective asset, now moving forward, hopefully soon, in three pivotal trials. In second line, hormone receptor positive, HER2 negative, breast cancer. We announced a couple of weeks ago that we'll have this trial fully enrolled by the middle of 2027. We feel very confident about being successful in that we have shown earlier this year at Esmotat an 11-month PFS, and we're going head-to-head with the market leader here that has a billion-dollar run rate of sales, Capiv Assertive, with its five-and-a-half-month PFS. So we're very excited about having this trial fully enrolled and starting to move towards commercialization. In our frontline hormone receptor positive HER2 negative breast cancer, we showed data earlier this year that shows that we have a very tolerable combinable regimen with Pfizer's selective CDK4 termocyclib, and we showed a very robust response rate in very late-line patients. And so we're excited about pushing this forwards and starting We'll provide a full regulatory update on the design of that trial later this year. And then finally, in vascular anomalies, we showed data back in May at ISFA that showed what we believe to be a very differentiated therapy, where we showed a 60% response rate in these patients, where the standard of care has shown something between 17% and 27%. And so, again, we will show data at ASH in December that will update the data that we We showed back in May, and we'll also provide a regulatory update around the design and pathway to what we believe will be an accelerated approval. Behind that, we have an NRAS selective inhibitor that entered the clinic early this year that we're very excited about. It could be used in melanoma and colorectal and other solid tumors, and we have $849 million of cash. It should take us well into 2029. Hopefully, we'll be able to generate lots of value, creating data between now and then.

Akash, Analyst — J.P. Morgan

Love it. And actually, I'm going to start with a topic which is a little more off left field. But I think you have an enviable cash position. But I think to your team's credit, you've really thought about capital allocation. When I look at the theoretical return on capital on your orphan drug development, I mean, the study is probably, I don't know, $50 to $100 million. The sales force can't be so large, but you almost have, like, two different distinct business models. You have a breast cancer development strategy. You have an orphan development strategy as well. How do you think about kind of running both of those in parallel and then also getting to value inflection points for investors who, you know, some might not have the patience to wait until, you know, the first line triple readout happens with the termo, but they're really interested in understanding the commercial development in, you know, PROS and LM.

Sanjeev Patel, CEO

Look, I think having an asset like Zovega that can be deployed in multiple indications has been super useful in building an enduring high-value company. And as you rightly point out, we expect the vascular anomalies trial to go very rapidly and the commercial bill there to be manageable. It's kind of rare disease-like in its look. And for us to generate revenues with relatively low outlay compared to breast cancer, which will come next. There in breast cancer, again, we think that it's a very large market with Capi for Certi's billion dollars of sales, and they've shown that, you know, over the two years since launch. And again, we think in the U.S. it's a well-circumscribed market that, you know, you know how to invest to get it. And then obviously if you wait slightly longer, you'll get the front line. So it kind of stacks upon each other. And then in the middle of that, obviously, we have our NRAS asset that could also generate value. And there are definitely other indications for Zorvega. As you know, you can rightly move into the adjuvant setting and go for an even larger slice of the pie, and you can go into hormone receptor-positive, HER2-positive, as well as other solid humans like endometrial. So we think it should provide investors with many ways to create value, but also to do it in a nice, structured way where we can build different tiers to the cake over time, and we should be able to do it with the capital that we have.

Akash, Analyst — J.P. Morgan

Understood. I'll press you on that a little bit more because, you know, it's interesting, and this is not a story unique in biotech. Sometimes you'll have a company with, you know, two different markets, two huge opportunities, and sometimes keeping them in one asset, you know, you end up, you know, some people are interested in, you know, the breast cancer opportunity. Some people are interested in the orphan opportunity. I think there's a general sense with investors that, you know, you want to keep both. Right. But I'm curious how you think about this pragmatically, too. Is there an opportunity for Relay to kind of unlock strategic value for one of these assets sooner than maybe investors expect that would then in turn put you in an even stronger position with another one of your bets? Right. I'm sure you have those discussions internally. How close is that to maybe being a reality?

Sanjeev Patel, CEO

Look, I think we all the time look at all the strategic options. To build an enduring biotech takes a lot of capital and the resources and focus of the team. And so if there is an opportunity at any point along the journey that could unlock value, we'll be open to it. I think if you just look at the two sides of it, they're very different. The vascular anomaly side looks much more manageable for us in the short term to commercialize. But we feel very confident about our ability to commercialize, especially in the U.S. breast cancer. The OUS breast cancer build may be more challenging for us, and so that may be an opportunity for us to unlock value. As you know, we've just hired a head of commercial that has launched brands both in breast cancer and in vascular anomalies. So we do feel very confident about both executing on the development side. As we just showed a couple of weeks ago, we've been able to enroll our second-round trial 12 months faster than anyone else has been able to, in the same indication. And so we're not at all in any way kind of feeling that we can't do the development side of this better than anyone else can. And so I think that will translate back into the commercial side as well.

Akash, Analyst — J.P. Morgan

Understood. And then maybe just last question on this. You know, there was an M&A panel and, you know, you had J&J, Lily, several of the big farmers, and they all, they, you know, the one piece of advice they gave externally, which was, When you go into a discussion with the pharma, don't come with a set of framework of, well, this is the value, this is what I want to do, and if not, take a hike. Do you feel like by having two disparate but, I would argue, equally exciting product opportunities puts you in a better or worse place strategically with external partnership discussions? Do you feel like sometimes it's like if someone could assign a value to one, it actually ends up unlocking strategic discussions for another avenue?

Sanjeev Patel, CEO

Look, you know, as you know, the... The world of what goes on in the mind of a big farmer is not really for me to speculate. All I can do is run a company that's going to be as successful as possible and generate as much value as I can, and we have multiple ways to generate value here. And so that should provide, with anyone from the outside in here, there are many ways to win here at Relay. It isn't a binary outcome. The vascular anomalies trial, which you've seen the data, is super compelling. The second-line trial looks equally compelling. The front-line trial looks great. Probably the lowest-risk trial we'll ever run. And then, obviously, you have these other opportunities. So I think the best way for us to be attractive to another company is just do our job right.

Akash, Analyst — J.P. Morgan

Understood. Now, going into your update at ASH, and, you know... Help us understand kind of the bar. There's a range of outcomes. You know, you had really, really positive data at the start of the year. There's kind of, I think, three elements here. One is the kinetics of response, right? So for some of these patients, you're getting several scans on them, and so I would love to get your expectation on how does that deepen over time. Number two, we think about... Maybe a dose that you move forward with, and then how much data are we going to get with that, you know, theoretical go-forward dose at your ASH update? And then the third part is really thinking about safety. What's the optimal safety profile you see with the selective allosteric PIK3-alpha that you feel like you really want to deliver on?

Sanjeev Patel, CEO

Yes, let me take those one at a time. So as you may remember, those of you who follow us, we showed 32 patients' worth of data at ISFA back in May, and all of those were in the safety database, but only 20 of those patients were efficacy-evaluable, and that's how we got to the 60% response rate, which compares very favorably to our Pelosib, which sits somewhere between 17% and 27%. So what we'll show this time is extended follow-up of those patients. And so they had a median follow-up of 14 weeks back in May. And so here we are now close to, you know, the middle of November. So they're going to have an extended degree of follow-up. So the key thing to look forward to there and see is, is there any kind of change in the safety profile that we showed? Did the toxicity stack up over time? Are going in hypotheses is they don't. And so that would be good to see. And then on the efficacy, all 32 patients will now be efficacy evaluable. And so the thing to look at here is in this larger N, as it moves from 20 to 32, can we maintain in and around the 60% response rate? If we could, I think that would be very reassuring to investors. The point on kinetics is also very clear, which is in the higher doses that we used, we showed very rapid, deep responses. And in the low dose, what we saw was shallow responses, but a lower rate of responses. So the thing that I think we're all looking to see is, do those lower dose patients slowly drift down over time and become responses? And then does the actual 60% response rate actually increase over time? I think that would give investors a lot of reassurance that this profile of the molecule at the lower doses would be attractive. And then to your point on safety, I think after the ISFA disclosure, obviously we spent the last six months engaging with the physician community in this space. What they want more than anything else is a chronic therapy. They are less fussed about rapid responses or the depth of responses. What they want is a therapy that patients can take for life. And so they are laser focused on the safety profile. And so what we need to deliver is an efficacy profile that clears the bar for any kind of FDA approval, clearly is differentiated from Alpalacib in its kind of mid-20s response rate, but is clean. Clean being very, very low rates of grade-3 toxicity, even low rates of grade-2 toxicity, and something that you could give an adolescent or a child for life. And so that's our hope when we show the doses and the data from the expansion cohorts. The majority of those patients in the expansion cohort are dosed at 400 milligrams once a day. And so the thing to look at there is what's the safety profile look like? Does it look as clean as we want it to be for chronic dosing? And then does it pass the efficacy bar? The efficacy bar here is just incrementally better than alpalacid. These patients that will show, they'll be a robust enough number for us to be interpretable, but we'll only show, you know, most of them will only have had one scan. And so if you can incrementally get over the alpalosib hurdle, I think you'd feel very confident that you would have a very good TPP here.

Akash, Analyst — J.P. Morgan

Hmm. Understood. Now, and actually just remind us, you know, I remember talking with your team recently, and in terms of accelerated approval and kind of error bars on the lower end, you have a view of what a response rate you would, you know, what's that hurdle you need to clear? Can you just remind us on the investor side, what's your interpretation of FDA guidance here on accelerated approval?

Sanjeev Patel, CEO

Yeah, I mean, I think, you know, we'll provide a regulatory update at ASH as long as at the same time we provide the data update. We can go into, you know, more detail about that. But specifically on your question, what we saw from the Novartis trials is that all Novartis had to do to be successful in their trials was have the lower bound of the confidence interval exclude 15% response rate. And so in their accelerated approval trial, they did exactly that, but they didn't do that in their confirmatory trial. So our view with the FDA is to hold us to that same standard, and obviously that will then allow us to size the trial appropriately and make sure that we can definitely exclude that.

Akash, Analyst — J.P. Morgan

Understood. Now, thinking about kind of toxicity and hypoglycemia, it's hard, you know, like we're doing work on this as well. It's kind of tricky because I think it was like 5 out of 11 patients in that 300 dose were pre-diabetic. That's right. So what I've been looking at mostly is really discontinuations more than anything else. But there is going to be investor focus on, you know, hyperglycemia rates and also the severity of it as well. As you think about your optimal profile, let's say for. The broader population, but also just even non, you know, like the non-pre-diabetic patients, what do you want to see from a hypoglycemia rate that you feel would be differentiated?

Sanjeev Patel, CEO

Look, overall, the goal here is to have, you know, very low rates of discontinuation. And what we saw in the initial 32 patients back at ISFRA is, you know, we had no discontinuations. And so that's the ultimate goal here, because the ultimate goal of clinicians is to keep these patients on therapy forever. And so in terms of hyperglycemia, you want to have rates that don't lead to discontinuation. So what does that mean? I think grade three hyperglycemia rates are going to be very difficult for patients to tolerate chronically. And so I think that's the biggest kind of flag for us. And so, as you know, grade two hyperglycemia can be medically managed. And so we want to make sure that any kind of hyperglycemia stays in that grade one, grade two, and that we see virtually no grade three.

Akash, Analyst — J.P. Morgan

Understood. Maybe just the last question on this. It almost does seem like maybe, and this is my interpretation, could there be two doses, right? Like maybe you have one dose where, you know, you're offering really strong exposure. You want to get, you know, the scans down as quickly as possible. Then there's another dose. Like maybe a clinician would want an option of, I've inducted a patient. Now I can get them onto a lower dose and kind of maintain them. Is that something your team's thinking about? Because I feel like on the investor side, we're like, okay, it's 400 McQD dose, and that'll be what you're taking forward. Do you feel like there might be room for multiple doses in your kind of expansion trial?

Sanjeev Patel, CEO

We don't think so. And again, it comes from like a detailed kind of understanding of the field, which is, you know, when we first came at this, you know, we looked at it in a kind of cancer lens, because that's where we come from. And that, you know, what do people want there is rapid debulking of the tumor. And that's how people judge success, rapid onset of response. In this field, these patients have been born with these lesions. And so what's not really important to people is the speed of which the lesions shrink. What's important to people is the tolerability of the profile, and then obviously is the patient-reported outcomes. And so what patients have seen, what clinicians have reported to us, is even at small levels of debulking of these lesions, you see actually symptomatic improvement in patients' diaries. And so that's why we think that a dose that is essentially tolerable is much more important than rapid debulking. So initially we had considered this question around should there be like a high-dose induction then followed by, you know, a low-dose maintenance. But we don't think that that's what patients want. And actually in practice you may actually see the opposite, which is people starting with lower doses and then slowly building up because they worry about the chronicity of dosing. And that's essentially what we see with alpalosib. And so we want to try and avoid that by just going for a dose that's effective and is tolerable.

Akash, Analyst — J.P. Morgan

Understood. Now, maybe turning gears to PIK3-alpha, and, you know, it goes back to this kind of question of, like, unlocking... You know, de-risking, and does it happen when a clinical trial reads out, or does it happen maybe before that? You know, I cover large-cap pharma. When I talk to the biggest breast cancer players in the space, it's, you know, cyclin-E. It's going to be, you know, an endocrine backbone. But the majority of major players in breast cancer. Are telling you PIK3 alpha is going to be a part of that kind of trifecta in terms of fundamental ways that we're going to be treating HR positive. How do you think, you know, let's put it this way for you have a triplet update coming up. And I think a lot of people will be like, oh, it's not survival data. You've got to prove it in a phase three study. And I don't think that's the right lens to really think about that. But at the same time, notably, you're actually delaying that a little to get some PFS data and get longer term follow-up. So how de-risking is that triplet update going to be? And what's the right way to kind of read it externally?

Sanjeev Patel, CEO

I think the way to think about the triplet is the data we showed earlier this year was the real kind of major update. Because the real question was, can you combine with a termocyclic and show, first of all, a better tolerability profile than we've ever seen before? And I think we've shown that. And I think the data that then followed it with 4Lite1 being read out at ESMO really reinforced that. The CDK4 from Pfizer has a very good rate of neutropenia in comparison to ribo or palbo. And it has an excellent rate of diarrhea in comparison to Obama. So we think that the de-risking of CDK4 as the backbone has already been done. And obviously, you've seen robust data sets from Zovega showing that we've been able to dial out the hyperglycemia, diarrhea, rash, dermatitis. And then, obviously, you saw the combination data of Zovega with Aterma. So I think on the safety profile, we've already shown that we've de-risked that. The data that you'll see later next year will obviously just reinforce that. But I don't think it'll be paradigm-changing. And on the efficacy side, with our 44% response rate, I think there you see the impact of a triplet. That 44% came in, you know, median third-line patients. The four-light one data just showed a 19% response rate for the doublet in the same kind of – it was actually a median second-line population. So you know that the efficacy is additive. So actually, I think you know everything you need to know about the triplet already. And actually, we've already made our decision to invest and then run the trial. So I think the data you'll see next year is purely incremental.

Akash, Analyst — J.P. Morgan

That's very helpful. And now we go into kind of your second-line study, and you're going head-to-head against CAPI. Enrollment proceeded quicker than expectations. Generally, we don't really think about interim analyses, I think, in second-line breast cancer, but I will dare to ask. Do you think there is a potential? Because you've laid out, like, you know, we think Cappy's six months, seven months. We have a view of where our drug's going to be. Is there a potential for an interim readout with that second-line study next year?

Sanjeev Patel, CEO

So first of all, yes, enrollment did go much faster than I think we've ever seen. I think we enrolled it 12 months faster than any of the precedents. In terms of just the speed of which the events come in now, we'll see how they accrue. But we just think that the interim analysis will come too close to essentially the final analysis to be useful. So I think we don't see a position for any kind of interim look at the data.

Akash, Analyst — J.P. Morgan

Okay. Very helpful. Maybe just at a point that I feel like doesn't get appreciated enough, I also asked this as a Pfizer analyst. You know, I think, you know, we're doing work right now on for like three and 1500 patients in that study head to head against lead with a doublet. Powering those studies are really, it's really tricky. And we saw that in the second line trial as well. But there is a potential that, you know, you may actually get on the market first as a approved PIK3 alpha agent before, let's say, a termocyclic gets approved as a CDK4. So for investors who might feel anxious, This is a novel, novel combo, and that means that the path to development might be trickier. Why is that maybe not the case? And let's say that, you know, your drug is approved and a termo is actually the novel agent. What's the regulatory path there?

Sanjeev Patel, CEO

So I think both trials are ongoing. Our Rediscover 2 trial is ongoing, and as you know, we hope it gets to approval rapidly, and it gets on the market in the second line. Their 4Lite 3 trial, we know it's fully enrolled, and hopefully they get in the market in the front line as well. And both agents are then approved, and then I think the questions are kind of put to bed. In the event that 4.0.3 ran out negative, I think is the kind of question with investors. I think for us, the 4.0.1 data that came out a couple of weeks ago is significantly de-risking because the 4.0.3 trial is a superiority trial, and so it has to be adequately powered to show that. I think for us in the triplet, all we really need is that a termocyclic tolerability backbone remains Because, obviously, we care about combining something that could be equivalent to the current CDK4-6s. It just needs to be more tolerable. And I think the 4-light one showed that that is clearly the case. And so in the event that 4-light 3 was, in fact, negative, we would file for approval. Hopefully, Zorvega would be an approved asset, and the first approval for a term recyclable would be in the combination. Now, on Pfizer's side, obviously, this provides a significant insurance policy to them in that, you know, 40% of the market then could still be accessible to a termocyclic in a failed 4-light-3 scenario.

Akash, Analyst — J.P. Morgan

Understood. I think maybe taking a step back and thinking about, you know, like Pfizer has their own PIK3 Alpha in development. Not shocking. I think if you're interested in PIK3 Alpha, you have an internal drug discovery team. That's not going to be an irrational decision. But I think the sense your team has, and I probably share this too, it's going to be really hard for other molecules to differentiate versus what you're providing. Why is that true? And what specific metrics about whether it's the PK, whether it's about the discontinuation rates, you feel very confident that your drug is kind of future-proofed with other PIK3 alphas that are in the clinic right now?

Sanjeev Patel, CEO

Look, I think we've shown a step change in efficacy and safety across the board against the non-selective inhibitors. And then, obviously, with the mutant selective inhibitors that are in the clinic, yes, there are different claims, slightly better coverage, lower dose, different selectivity profiles. I think what we have seen now in the doublet and then specifically even more in the triplet is that we don't think this is going to matter to be slightly better. You're going to have to be a step change better. And so it isn't, you know, if we put up 11 months and someone puts up 11 and a half months, it's not going to matter commercially because we'll be in the market, you know, three to five years ahead of these folks. So what we need to see is someone put up 15 months and just to take out the toxicity profile down to, you know, only grade one toxicities. And so what we see from some of these early assets is that seems very difficult, a TPP, to meet with what we're seeing.

Akash, Analyst — J.P. Morgan

Yeah, and maybe just lastly on this point, because again, you probably have unique insights on this. You've tested more selective approaches, and you look at the loxer drug. To me, there actually seems to be this relationship. The more selective you get, the harder it is to actually have a nice drug accumulation of fat. Flat PK profile. You know, is there any comments you can make about the tradeoff on selectivity versus getting an optimal drug-like quality for your PIK3 album?

Sanjeev Patel, CEO

Yeah, look, we looked, you know, we probably studied the target more than anyone else. We probably developed more PIK3 inhibitors than anyone else has ever developed. And we like Zovega. We think it has a great PIK profile. Its selectivity profile may be optimal. And actually, you see, maybe you even see the same thing on the CDK4 side, which is, you know, Is a super-selective CDK4 actually going to be detrimental versus a CDK4 that has a little bit of CDK6 activity? So it could be a generalizable concept that actually super-selective may not be best.

Akash, Analyst — J.P. Morgan

Understood. I really do appreciate it. I covered a lot of ground, and thanks so much. Always enjoy the combos.

Sanjeev Patel, CEO

Thanks very much. Thanks.